Desamino-D-Arginine Vasopressin and Bleeding Time in von Willebrand's Disease
Authors: LOUIS ISOLA
Journal: Annals of Internal Medicine (1984)

Letters and Corrections1 November 1984Desamino-D-Arginine Vasopressin and Bleeding Time in von Willebrand's DiseaseLOUIS ISOLA, M.D., ALICE FORSTER, R.N., LOUIS M ALEDORT, M.D.LOUIS ISOLA, M.D.Search for more papers by this author, ALICE FORSTER, R.N.Search for more papers by this author, LOUIS M ALEDORT, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-101-5-719_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Desamino-D-arginine vasopressin has been reported to be a useful prophylactic as well as therapeutic agent in the management of patients with mild hemophilia, von Willebrand's disease, and uremic bleeding disorders (1, 2). Until recently, replacement therapy was the only treatment available for this group of patients. This treatment is associated with the risk of transmission of various viral diseases, inhibitors, immune complexes, and more recently, the acquired immunodeficiency syndrome.The mechanisms that alter bleeding time and raise factor VIII as well as von Willebrand factors after desamino-D-arginine vasopressin are not fully understood. The changes in hemostatic components...References1. MANNUCCIRUGGERIPARETICAPITANO PZFA. 1-desamino-8-D-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrand's disease. Lancet. 1977;1:869-71. CrossrefMedlineGoogle Scholar2. MANNUCCIREMUZZIPUSINERIZIMMERMAN PGFT. Desamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983;308:8-12. CrossrefMedlineGoogle Scholar3. SCHMITZ-HUEBNERBALLEISENARENDSPOLLMANSUTOR ULPHA. DDAVP-induced changes factor VIII related activities and bleeding time in patients with von Willebrand's syndrome. Haemostasis. 1980;9:204-13. MedlineGoogle Scholar4. RUGGERIMANNUCCIZIMMERMANLOMBARDIFEDERICI ZPTRA. Multimeric composition of factor VII/von Willebrand factor following the administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes. Blood. 1982;59:1272-8. CrossrefMedlineGoogle Scholar5. THEISSSCHMIDT WG. DDAVP in von Willebrand's disease: repeated administration and the behavior of the bleeding time. Thromb Res. 1978;13:1119-23. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Mt. Sinai Medical Center New York, NY 10029 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByCan we prevent inhibitors in mild and moderate factor VIII-deficient patients?Clinical Experience in Disorders of HaemostasisNew Approaches to Management of Bleeding DisordersDDAVP in the Treatment of Bleeding DisordersVasopressin Analogues. 1 November 1984Volume 101, Issue 5Page: 719-720KeywordsDiagnostic medicineHematology and oncologyHemophiliaHemorrhageHemostaticsImmune complexMedical servicesVasopressinViral diseasesvon Willebrand disease Issue Published: 1 November 1984 PDF DownloadLoading ...